Cytek Biosciences (CTKB) vs Revvity (RVTY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Revvity (RVTY) has outperformed Cytek Biosciences (CTKB) over the past year, gaining 68.4% versus a gain of 40.9%. Over five years, RVTY leads with a -9.6% price change compared with -77.8% for CTKB. Revvity is the larger company by market cap ($16.57 billion vs $677.9 million), about 24.4 times the size.
On valuation, Revvity trades at a lower forward P/E (25.2x vs 74.5x for Cytek Biosciences). Revvity pays a dividend yielding 0.19%, while Cytek Biosciences does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTKB | RVTY |
|---|---|---|
| Share price | $5.22 | $148.52 |
| Market cap | $677.86M | $16.57B |
| 1-day change | -2.34% | -3.31% |
| YTD return | +5.74% | +58.76% |
| 1-year return | +40.90% | +68.44% |
| 5-year return | -77.81% | -9.55% |
| P/E ratio (TTM) | — | 71.06 |
| Forward P/E | 74.50 | 25.20 |
| EPS (TTM) | $-0.62 | $2.09 |
| Dividend yield | 0.00% | 0.19% |
| Annual dividend | $0.00 | $0.28 |
| Revenue (latest FY) | — | $2.86B |
| Revenue growth (YoY) | — | +3.67% |
| Net income (latest FY) | — | $241.20M |
| Operating margin | — | 12.49% |
| Net margin | — | 8.45% |
| 52-week high | $6.21 | $166.25 |
| 52-week low | $3.31 | $81.22 |
| Distance from 52-week high | -16.02% | -10.66% |
| Analyst consensus | none | buy |
| Avg. price target upside | +6.62% | -8.52% |
| Average volume | 1.04M | 1.79M |
| Shares outstanding | 129.98M | 111.59M |
| Employees | 682 | 11,000 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Revvity is about 24.4 times larger than Cytek Biosciences by market value ($16.57B vs $677.86M).
- RVTY has outperformed CTKB by 27.5 percentage points over the past year.
About Cytek Biosciences
CTKB stock →Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 682 employees
About Revvity
RVTY stock →Revvity, Inc. provides health sciences solutions, technologies, and services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,000 employees
CTKB vs RVTY FAQ
Which is bigger, Cytek Biosciences or Revvity?
Revvity (RVTY) is larger, with a market capitalization of $16.57B compared with $677.86M for Cytek Biosciences (CTKB).
Which stock has performed better over the past year, CTKB or RVTY?
RVTY returned +68.44% over the past 12 months, compared with +40.90% for CTKB (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Cytek Biosciences or Revvity?
Revvity pays a dividend yielding 0.19%, while Cytek Biosciences does not currently pay a regular dividend.
Are Cytek Biosciences and Revvity in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.